Credit rating agency, CARE has reaffirmed ‘AAA’ rating to Cipla’s Long-term Bank Facilities worth Rs 72.38 crore. The rating agency has also reaffirmed A1+ rating to the company’s Short-term Bank Facilities worth Rs 1723.50 crore.
The reaffirmation of the ratings continues to reflect Cipla’s leading market position in respiratory segment, stable business performance, continuing strong financial profile characterized by low gearing levels and a healthy liquidity position. The ratings also positively build in the long and successful track record of the company spanning over 78 years, experienced and professional promoters and management, wide geographical presence and its well-diversified product portfolio.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |